Gilead Sciences, Inc. (NASDAQ:GILD) Announces $0.77 Quarterly Dividend

Gilead Sciences, Inc. (NASDAQ:GILD) announced a quarterly dividend on Wednesday, November 6th,Zacks Dividends reports. Shareholders of record on Friday, December 13th will be paid a dividend of 0.77 per share by the biopharmaceutical company on Monday, December 30th. This represents a $3.08 annualized dividend and a dividend yield of 3.20%. The ex-dividend date is Friday, December 13th.

Gilead Sciences has raised its dividend by an average of 3.3% annually over the last three years. Gilead Sciences has a payout ratio of 42.4% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $7.28 per share next year, which means the company should continue to be able to cover its $3.08 annual dividend with an expected future payout ratio of 42.3%.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $1.60 on Friday, hitting $96.30. The company’s stock had a trading volume of 2,385,501 shares, compared to its average volume of 7,024,102. Gilead Sciences has a 12-month low of $62.07 and a 12-month high of $98.32. The company has a market capitalization of $119.89 billion, a price-to-earnings ratio of 118.29, a price-to-earnings-growth ratio of 3.13 and a beta of 0.17. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The stock has a 50 day moving average of $84.58 and a 200-day moving average of $74.67.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 earnings per share. As a group, research analysts predict that Gilead Sciences will post 3.75 EPS for the current year.

Wall Street Analyst Weigh In

GILD has been the subject of a number of analyst reports. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research report on Thursday. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Barclays upped their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Thursday. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Sanford C. Bernstein started coverage on shares of Gilead Sciences in a research report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target for the company. Twelve investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $90.71.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 62,437 shares of company stock worth $5,374,825. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.